Question 8729 — diseases

Summary

Mr. Jean-Pierre Door draws the attention of the Minister of Solidarity and Health to prostate cancer with bone metastases. Prostate cancer ranks first among cancers in men and represents the third cause of death from tumors in men in France. It kills more than 8,300 patients per year in France, 2,600 of whom suffer from bone metastases, or more than 50 deaths per week! But a solution exists but is still not offered to French patients, while this has been the case in the rest of Europe since 2013. In fact, radium 223 dichloride (known under the name Xovigo) is the first emitter of alfa particles which target bone metastases. Currently, Xovigo is prescribed and supported in 27 countries, including 23 in Europe. In Germany, it has benefited 3,641 patients since 2013 (i.e., in 216, 1,313 patients). In In England in 2016, there were 988 patients, 327 in Spain, 356 in the Netherlands and 456 in Italy who were treated. In France, only 64 patients were able to benefit from this treatment. He therefore asks what measures the Government intends to take to urgently authorize the coverage of this treatment in France.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.